跳至主要内容
临床试验/ACTRN12613001009707
ACTRN12613001009707已完成未知

ANZ 1302A - An online survey to evaluate the incidence and clinical impact of aromatase inhibitor-induced musculoskeletal syndrome (AIMSS) in Australian women with a diagnosis of breast cancer since 2007 being treated with an adjuvant aromatase inhibitor currently or since their diagnosis

Australia and New Zealand Breast Cancer Trials Group0 个研究点目标入组 500 人开始时间: 2013年9月11日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
Female

入选标准

  • •1) Must be female, >=18 years
  • •2) Must have a diagnosis of Early Breast Cancer (stage 1-3) in 2007 or later
  • •3) Must be taking adjuvant AI in any setting (up-front, switch, extended) currently or at any time since their breast cancer diagnosis
  • •4) Must be able to provide informed consent

排除标准

  • •1) Insufficient English language skills for participation
  • •2) Diagnosis of DCIS only or with metastatic breast cancer

研究者

发起方
Australia and New Zealand Breast Cancer Trials Group

相似试验